60 related articles for article (PubMed ID: 17910895)
1. Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells.
Zagon IS; Rahn KA; McLaughlin PJ
Neuropeptides; 2007 Dec; 41(6):441-52. PubMed ID: 17910895
[TBL] [Abstract][Full Text] [Related]
2. Featured Article: Serum [Met
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2017 Sep; 242(15):1524-1533. PubMed ID: 28766982
[TBL] [Abstract][Full Text] [Related]
3. Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin.
Purushothaman I; Zagon IS; Sassani JW; McLaughlin PJ
Biochem Pharmacol; 2021 Oct; 192():114712. PubMed ID: 34324868
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy.
Ciwun M; Tankiewicz-Kwedlo A; Pawlak D
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539570
[TBL] [Abstract][Full Text] [Related]
5. Role of differential adhesion in cell cluster evolution: from vasculogenesis to cancer metastasis.
Singh J; Hussain F; Decuzzi P
Comput Methods Biomech Biomed Engin; 2015; 18(3):282-92. PubMed ID: 23656190
[TBL] [Abstract][Full Text] [Related]
6. The mu opioid receptor: A new target for cancer therapy?
Singleton PA; Moss J; Karp DD; Atkins JT; Janku F
Cancer; 2015 Aug; 121(16):2681-8. PubMed ID: 26043235
[TBL] [Abstract][Full Text] [Related]
7. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.
Lennon FE; Mirzapoiazova T; Mambetsariev B; Poroyko VA; Salgia R; Moss J; Singleton PA
PLoS One; 2014; 9(3):e91577. PubMed ID: 24662916
[TBL] [Abstract][Full Text] [Related]
8. Novel treatment for triple-negative breast and ovarian cancer: endogenous opioid suppression of women's cancers.
McLaughlin PJ; Zagon IS
Expert Rev Anticancer Ther; 2014 Mar; 14(3):247-50. PubMed ID: 24397732
[TBL] [Abstract][Full Text] [Related]
9. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817
[TBL] [Abstract][Full Text] [Related]
10. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation.
Mathew B; Lennon FE; Siegler J; Mirzapoiazova T; Mambetsariev N; Sammani S; Gerhold LM; LaRiviere PJ; Chen CT; Garcia JG; Salgia R; Moss J; Singleton PA
Anesth Analg; 2011 Mar; 112(3):558-67. PubMed ID: 21156980
[TBL] [Abstract][Full Text] [Related]
11. Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases.
Berkson BM; Rubin DM; Berkson AJ
Integr Cancer Ther; 2009 Dec; 8(4):416-22. PubMed ID: 20042414
[TBL] [Abstract][Full Text] [Related]
12. Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy.
Liu WM; Scott KA; Dennis JL; Kaminska E; Levett AJ; Dalgleish AG
Int J Oncol; 2016 Aug; 49(2):793-802. PubMed ID: 27279602
[TBL] [Abstract][Full Text] [Related]
13. Effect of low dose naloxone on the immune system function of a patient undergoing video-assisted thoracoscopic resection of lung cancer with sufentanil controlled analgesia - a randomized controlled trial.
Lin Y; Miao Z; Wu Y; Ge FF; Wen QP
BMC Anesthesiol; 2019 Dec; 19(1):236. PubMed ID: 31856760
[TBL] [Abstract][Full Text] [Related]
14. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.
Wang R; Zhang Y; Shan F
Int Immunopharmacol; 2019 Oct; 75():105785. PubMed ID: 31404891
[TBL] [Abstract][Full Text] [Related]
15. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
Zagon IS; Donahue R; McLaughlin PJ
Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
[TBL] [Abstract][Full Text] [Related]
16. Morphine Analgesia, Cannabinoid Receptor 2, and Opioid Growth Factor Receptor Cancer Tissue Expression Improve Survival after Pancreatic Cancer Surgery.
Vecera L; Prasil P; Srovnal J; Berta E; Vidlarova M; Gabrhelik T; Kourilova P; Lovecek M; Skalicky P; Skarda J; Kala Z; Michalek P; Hajduch M
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627066
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the Opioid Peptide Family in Cancer Progression.
Sánchez ML; Rodríguez FD; Coveñas R
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509632
[TBL] [Abstract][Full Text] [Related]
18. Influence of opioid analgesia type on circulating tumor cells in open colorectal cancer surgery (POACC-1): study protocol for a prospective randomized multicenter controlled trial.
Berta E; Srovnal J; Dytrych P; Bruthans J; Ulrichova J; Prasil P; Vecera L; Gabrhelik T; Tolmaci B; Dusa J; Maca J; Mazancova M; Haiduk F; Kutej M; Ihnat P; Michalek P; Hajduch M
BMC Anesthesiol; 2023 Feb; 23(1):64. PubMed ID: 36855089
[TBL] [Abstract][Full Text] [Related]
19. The expression of kappa-opioid receptor promotes the migration of breast cancer cells in vitro.
Li H; Ma Z; Lei Y
BMC Anesthesiol; 2021 Aug; 21(1):210. PubMed ID: 34461834
[TBL] [Abstract][Full Text] [Related]
20. Opioid growth factor and the treatment of human pancreatic cancer: a review.
Zagon IS; McLaughlin PJ
World J Gastroenterol; 2014 Mar; 20(9):2218-23. PubMed ID: 24605021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
